By taking two approaches to COVID-19 immunity – active and passive – Biotav is expediting protective immunity compared to other means of immunizing populations against mutating and adaptive strains of viruses.
Based on a modified, asymptomatic version of the virus, Biotav’s live attenuated vaccine is expected to show extremely high efficacy compared to forecasts for recombinant vaccines and nucleic acid vaccines currently in development. For passive immunity, Biotav has developed a hyperimmune Yolk Immunoglobulin (IgY), over-the-counter mucosal spray, based on a proven approach and validated methodology. Administered at the stage where early signs of infection are present, this revolutionary solution ensures greater accessibility to treatment and immunization.
As both the nasal spray and the live attenuated vaccines are based on safe and proven biopharmaceutical approaches, solutions will be classified as a Class II devices, ensuring shorter development time and a faster response to the current pandemic and other EIDs.